New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2013
07:48 EDTREGN, BAYRYEylea gets backing from NICE for secondary use in macular edema
The U.K.'s National Institute for Health and Care Excellence announced it has published final draft guidance recommending aflibercept solution for injection, marketed under the trade name Eylea by Bayer (BAYRY), as an option for treating visual impairment caused by macular edema, a condition which affects a person's ability to see detail and color. The draft guidance relates to macular edema secondary to central retinal vein occlusion, or CRVO, where the vein to the retina is blocked. NICE recommends the treatment is only prescribed if the manufacturer makes it available to the NHS under terms agreed with the Department of Health as part of a patient access scheme. Bayer has a collaboration agreement with Regeneron Pharmaceuticals (REGN) for the global development of Eylea. Under the agreement, Regeneron owns the U.S. rights to the drug and Bayer is responsible for marketing the drug outside the U.S.
News For REGN;BAYRY From The Last 14 Days
Check below for free stories on REGN;BAYRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
07:32 EDTREGNRegeneron may be taking market share from Roche, says Brean Capital
Subscribe for More Information
05:20 EDTREGNRegeneron initiated with a Buy at Canaccord
Subscribe for More Information
April 10, 2014
07:24 EDTBAYRYInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
April 9, 2014
07:09 EDTBAYRYReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
April 8, 2014
11:03 EDTREGNPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
April 3, 2014
06:28 EDTREGNAtopic dermatitis could bring upside to Regeneron, Celgene, says Citigroup
Citigroup believes Regeneron's (REGN) dupilumab and Celgene's (CELG) Otezla for atopic dermatitis are being overlooked by investors and could provide upside for both names. Citi believes both drugs have good efficacy but adds that dupilumab is more advanced. The firm has a Buy rating on both stocks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use